Kornelis S. M. van der Geest

Kornelis S. M. van der Geest

Auto-generated profile, based on publicly available information

Kornelis S. M. van der Geest

Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2020 in JAMA Internal Medicine
Verified
Journal Article
Closed access
PDF file
KGKornelis S. M. van der Geest
Kornelis S. M. van der Geest
MSMaria Sandovici
Maria Sandovici
EBElisabeth Brouwer
Elisabeth Brouwer
SMSarah L. Mackie
Sarah L. Mackie
Giant cell arteritis (GCA) is a “do-not-miss” diagnosis. Prompt diagnosis can avert visual loss.1 Diagnosis can be delayed in those without the classic cranial features, such as headache.2 Treatment for GCA consists of high-dose glucocorticoids tapered during the course of 1 year or more, but this treatment may cause substantial toxic effects, so diagnostic uncertainty must be minimized.3

12 March 2014 in Arthritis & Rheumatology
Verified
Journal Article
Open access
PDF file
KGKornelis S. M. van der Geest
Kornelis S. M. van der Geest
WAWayel H. Abdulahad
Wayel H. Abdulahad
PCPaulina Chalan
Paulina Chalan
ARAbraham Rutgers
Abraham Rutgers
GHGerda Horst
Gerda Horst
EBElisabeth Brouwer
Elisabeth Brouwer
Objective: Several lines of evidence indicate that B cells may be involved in the immunopathology of giant cell arteritis (GCA) and polymyalgia rheumatica (PMR). This study was undertaken to examine the distribution of defined B cell subsets, including effector B (Beff) cells and regulatory B (Breg) cells, in patients with GCA and patients with PMR before and after corticosteroid treatment.Methods: Circulating B cells were analyzed in 34 newly diagnosed, untreated patients with GCA or PMR, and in 44 followup samples from patients with GCA or PMR who received corticosteroids for 2 weeks or 3 months. For comparison, 40 age‐matched healthy controls and 11 rheumatoid arthritis (RA) patients were included. Serum BAFF levels were determined, and temporal arteries were studied by immunohistochemistry.Results: Patients newly diagnosed as having GCA or PMR, but not patients with RA, had decreased numbers of circulating B cells compared to healthy controls. B cell numbers recovered rapidly in treated patients with GCA and PMR in remission. This recovery was not achieved by compensatory hyperproliferation or enhanced bone marrow production. B cell numbers inversely correlated with erythrocyte sedimentation rates, C‐reactive protein levels, and serum BAFF levels. Tumor necrosis factor α–positive Beff cells, but not interleukin‐10 (IL‐10)–positive Breg cells, were decreased in patients newly diagnosed as having GCA or PMR. Following treatment, circulating numbers of Beff cells normalized. The returning Beff cells demonstrated an enhanced capacity to produce IL‐6. Few B cells were found in temporal artery biopsy specimens from GCA patients.Conclusion: We show for the first time that the distribution of B cells is highly disturbed in GCA and PMR and that B cells likely contribute to the enhanced IL‐6 response in both diseases.

1 December 2014 in Experimental Gerontology
Verified
Journal Article
Closed access
KGKornelis S.M. van der Geest
Kornelis S.M. van der Geest
WAWayel H. Abdulahad
Wayel H. Abdulahad
STSarah M. Tete
Sarah M. Tete
PLPedro G. Lorencetti
Pedro G. Lorencetti
GHGerda Horst
Gerda Horst
ABAnnemieke M.H. Boots
Annemieke M.H. Boots

3 May 2021 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Open access
PDF file
KGK S M van der Geest
K S M van der Geest
GTG Treglia
G Treglia
AGA W J M Glaudemans
A W J M Glaudemans
EBE Brouwer
E Brouwer
MSM Sandovici
M Sandovici
RSR H J A Slart
R H J A Slart
Purpose: Monitoring disease activity in patients with large vessel vasculitis (LVV) can be challenging. [18F]FDG-PET/CT is increasingly used to evaluate treatment response in LVV. In this systematic review and meta-analysis, we aimed to summarize the current evidence on the value of [18F]FDG-PET/CT for treatment monitoring in LVV. Methods: PubMed/MEDLINE and the Cochrane library database were searched from inception through October 21, 2020. Studies containing patients with LVV (i.e. giant cell arteritis, Takayasu arteritis and isolated aortitis) that received treatment and underwent [18F]FDG-PET/CT were included. Screening, full-text review and data extraction were performed by 2 investigators. The risk of bias was examined with the QUADAS-2 tool. Meta-analysis of proportions and diagnostic test accuracy was performed by a random-effects model and bivariate model, respectively. Results: Twenty-one studies were included in the systematic review, of which 8 studies were eligible for meta-analysis. Arterial [18F]FDG uptake decreased upon clinical remission in longitudinal studies. High heterogeneity (I2 statistic 94%) precluded meta-analysis of the proportion of patients in which the scan normalized during clinical remission. Meta-analysis of cross-sectional studies indicated that [18F]FDG-PET/CT may detect relapsing/refractory disease with a sensitivity of 77% (95%CI 57–90%) and specificity of 71% (95%CI 47–87%). Substantial heterogeneity was observed among the cross-sectional studies. Both variation in clinical aspects and imaging procedures contributed to the heterogeneity. Conclusion: Treatment of LVV leads to reduction of arterial [18F]FDG uptake during clinical remission. [18F]FDG-PET/CT has moderate diagnostic accuracy for detecting active LVV. [18F]FDG-PET/CT may aid treatment monitoring in LVV, but its findings should be interpreted in the context of the clinical suspicion of disease activity. This study underlines the relevance of published procedural recommendations for the use of [18F]FDG-PET/CT in LVV.

12 June 2023 in Nature Reviews Rheumatology
Verified
Journal Article
Closed access
PDF file
ATAlessandro Tomelleri
Alessandro Tomelleri
KGKornelis S. M. van der Geest
Kornelis S. M. van der Geest
MKMuhammad Asim Khurshid
Muhammad Asim Khurshid
ASAlwin Sebastian
Alwin Sebastian
FCFiona Coath
Fiona Coath
BDBhaskar Dasgupta
Bhaskar Dasgupta

1 March 2020 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
KGKornelis S M van der Geest
Kornelis S M van der Geest
FBFrances Borg
Frances Borg
AKAbdul Kayani
Abdul Kayani
DPDavy Paap
Davy Paap
PGPrisca Gondo
Prisca Gondo
BDBhaskar Dasgupta
Bhaskar Dasgupta
Objectives Ultrasound of temporal and axillary arteries may reveal vessel wall inflammation in patients with giant cell arteritis (GCA). We developed a ultrasound scoring system to quantify the extent of vascular inflammation and investigated its diagnostic accuracy and association with clinical factors in GCA. Methods This is a prospective study including 89 patients suspected of having GCA, of whom 58 had a confirmed clinical diagnosis of GCA after 6 months follow-up. All patients underwent bilateral ultrasound examination of the three temporal artery (TA) segments and axillary arteries, prior to TA biopsy. The extent of vascular inflammation was quantified by (1) counting the number of TA segments and axillary arteries with a halo and (2) calculating a composite Halo Score that also incorporated the thickness of each halo. Results Halo counts and Halo Scores showed moderate diagnostic accuracy for a clinical diagnosis of GCA. They correlated positively with systemic inflammation. When compared with the halo count, the Halo Score correlated better with C-reactive protein (CRP) levels and allowed to firmly establish the diagnosis of GCA in more patients. Higher halo counts and Halo Scores were associated with a higher risk of ocular ischaemia. They allowed to identify subgroups of patients with low risk (≤5%) and high risk of ocular ischaemia (>30%). Conclusions Ultrasound halo scoring allows to quantify the extent of vascular inflammation in GCA. Extensive vascular inflammation on ultrasound may provide strong diagnostic confirmation and associates with ocular ischaemia in GCA.